Merkel Cell Carcinoma (MCC) Clinical Trials and Treatments

Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with aggressive behavior and high recurrence rates. It arises from Merkel cells, specialized mechanoreceptors in the basal layer of the epidermis. MCC is associated with two distinct etiologic pathways: Merkel cell polyomavirus (MCPyV) integration (80% of cases) and ultraviolet radiation-induced DNA damage (virus-negative MCC, which typically has very high mutational burden).

The most common symptoms of Merkel Cell Carcinoma include A firm, painless, dome-shaped nodule on the skin, Rapidly growing skin lesion, often red, blue, or purple, Usually appears on sun-exposed areas (head, neck, arms), Nodule may be shiny and flesh-colored to red, Rarely causes pain or itching in early stages, among others. About 3,000 new cases per year in the U.S.; incidence has tripled over the past 2 decades. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Merkel Cell Carcinoma from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. The approval of avelumab, the first checkpoint inhibitor specifically for metastatic Merkel cell carcinoma, marked a turning point for this rare cancer, and researchers are now building on that success. Pembrolizumab (Keytruda) and retifanlimab (Zynyz) are also FDA approved for advanced MCC.

Yes. As of October 21, 2026, 3 FDA-approved medicines have a current label that names Merkel Cell Carcinoma: Zynyz (retifanlimab-dlwr), first approved in 2023; Bavencio (avelumab); and Keytruda (pembrolizumab). Corticosteroids and immune globulins count once each.

Merkel Cell Carcinoma is an acquired condition, not an inherited one. About 70-80% of US cases are driven by clonally integrated Merkel cell polyomavirus and the rest by UV damage; no inherited gene test has a diagnostic role. About 3,000 new cases per year in the U.S.; incidence has tripled over the past 2 decades.

Eligibility for Merkel Cell Carcinoma clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Merkel Cell Carcinoma clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.